Litcius/Paper detail

Update on the STING Signaling Pathway in Developing Nonalcoholic Fatty Liver Disease

Wei Liu, Zhili Zhang Chen, Chenhui Yang, Yaofu Fan, Liang Qiao, Shaofeng Xie, Lin Cao

2023Journal of Clinical and Translational Hepatology16 citationsDOIOpen Access PDF

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition with limited treatment options. Inflammation caused by metabolic disturbances plays a significant role in NAFLD development. Stimulator of interferon gene (STING), a critical regulator of innate immunity, induces the production of interferons and other pro-inflammatory factors by recognizing cytoplasmic DNA to defend against pathogen infection. The STING-mediated signaling pathway appears to play a vital role in hepatic inflammation, metabolic disorders, and even carcinogenesis. Promisingly, pharmacological interventions targeting STING have shown improvements in the pathological state of NAFLD. Macrophages, dendritic cells, natural killer cells, and T cell pathways regulated by STING present potential novel druggable targets for NAFLD treatment. Further research and development in this area may offer new therapeutic options for managing NAFLD effectively.

Topics & Concepts

StingNonalcoholic fatty liver diseaseMedicineInflammationStimulator of interferon genesImmunologyInnate immune systemFatty liverDiseaseBioinformaticsCancer researchBiologyImmune systemInternal medicineAerospace engineeringEngineeringinterferon and immune responsesHepatitis C virus researchInflammasome and immune disorders